Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| VEGF / VEGFR | >90% | Clear-cell VHL loss drives VEGF (pathway prevalence) | cBioPortal (TCGA) |
| HIF-2α | 85-90% | VHL inactivation in clear-cell RCC | cBioPortal (TCGA) |
| CD70 | 80-90% | Clear-cell, IHC | Wikipedia |
| CDH6 | 60-80% | IHC, any expression | Wikipedia |
| PSMA Clear-cell; imaging studies | 60-80% | Neovascular PSMA expression | PMC |
| MET | 10-15% | Papillary RCC type 1 alterations | cBioPortal (TCGA) |
| mTOR Voss 2019 (Clin Cancer Res); TSC1 6%, TSC2 4.4%, any PI3K-pathway alteration 44%; mutation status did not predict everolimus benefit | 8.2% | Targeted NGS, MTOR mutation in 184 everolimus-treated RCC patients (RECORD-3) | doi.org |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
4 cell lines, 1 mouse models and 5 repositories are listed for this cancer. See them →